Susanne Jacobsson Selected Research

Gonorrhea

3/2023	Complete Reference Genome Sequence of the Clinical Neisseria gonorrhoeae Strain H035, with Resistance to the Novel Antimicrobial Zoliflodacin, Identified in Japan in 2000.
1/2023	Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model.
9/2022	Complete Reference Genome Sequence of the Extensively Drug-Resistant Strain Neisseria gonorrhoeae AT159, with Ceftriaxone Resistance and High-Level Azithromycin Resistance, Using Nanopore Q20+ Chemistry and Illumina Sequencing.
1/2022	Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
1/2022	Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections.
1/2021	Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.
1/2019	High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017).
9/2015	High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
1/2015	Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae.
9/2014	High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susanne Jacobsson Research Topics

Disease

14	Infections 04/2024 - 11/2017
10	Gonorrhea 03/2023 - 09/2014
5	Meningococcal Infections 12/2020 - 03/2009
3	Hypersensitivity (Allergy) 09/2019 - 01/2018
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2022 - 01/2015
1	Allergic Contact Dermatitis 05/2023
1	Urethritis 01/2023
1	Coinfection 01/2023
1	Bacterial Pneumonia 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018
1	Surgical Wound Infection 10/2014

Drug/Important Bio-Agent (IBA)

8	Azithromycin (Zithromax)FDA LinkGeneric 04/2024 - 01/2015
8	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 03/2024 - 01/2018
8	zoliflodacinIBA 03/2023 - 09/2014
3	DNA GyraseIBA 01/2023 - 01/2021
3	Ciprofloxacin (Cipro)FDA LinkGeneric 06/2022 - 10/2020
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2019
2	Doxycycline (Periostat)FDA LinkGeneric 01/2023 - 06/2021
2	VaccinesIBA 01/2020 - 03/2009
1	Carbon Fiber (Grafil)IBA 05/2023
1	Gentamicins (Gentamicin)FDA LinkGeneric 01/2023
1	lefamulinIBA 01/2022
1	PleuromutilinsIBA 01/2022
1	Cefixime (Suprax)FDA Link 03/2021
1	RNA (Ribonucleic Acid)IBA 12/2020
1	Virulence Factors (Pathogenicity Factors)IBA 12/2020
1	Polysaccharides (Glycans)IBA 12/2020
1	Capsules (Microcapsules)IBA 12/2020
1	InflammasomesIBA 01/2019
1	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2018
1	gepotidacinIBA 01/2018
1	FluoroquinolonesIBA 01/2018
1	sitafloxacinIBA 01/2018
1	Topoisomerase II InhibitorsIBA 01/2015
1	Local Anti-Infective Agents (Antiseptics)IBA 10/2014
1	A-Form DNA (A-DNA)IBA 09/2014
1	AntigensIBA 03/2009

Therapy/Procedure

4	Therapeutics 03/2024 - 01/2018
1	Critical Care (Surgical Intensive Care) 01/2021